NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

251.35B

Vuru Grade

68.09/100

Current Price

$103.85
-0.94 (-0.90%)

Growth Price

$63.47
Overvalued by 38.88%

Stability Price

$21.65
Overvalued by 79.16%

Company Metrics

  • 12.61 P/E
  • 4.81 P/S
  • 3.32 P/B
  • 8.24 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 2.67 / 2.6% Dividend
  • 1.31M Avg. Vol.
  • 2.42B Shares
  • 251.35B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales ...
Bidness ETC - May 23, 2015
New breast cancer drugs from Novartis AG (ADR) (NYSE:NVS) can add another $5 billion to global sales for the disease in 2020.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR ...
Bidness ETC - May 7, 2015
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY).
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets - WallStreetPR (blog)
GlaxoSmithKline scraps HIV spinout, reports higher Q1 profit - Proactive Investors USA & Canada
Novartis AG (ADR) Partners With Aduro Biotech With A $750 Million Deal
Business Finance News - Mar 30, 2015
Novartis AG (ADR) (NYSE:NVS) has announced a deal with cancer immunotherapy company, Aduro Biotech, Inc., in which both the companies will partner to research and manufacture treatments for cancer.
Novartis AG (ADR) Inks $750 Million Deal With Aduro Biotech - Bidness ETC
Novartis AG (ADR) CAR-T Drug Delays Cancer Progress
Bidness ETC - May 14, 2015
Novartis AG (ADR) (NYSE:NVS) has been actively seeking to establish a strong foothold in the highly lucrative immune-oncology drug market.
AstraZeneca plc (ADR), Novartis AG Combo Melanoma Drug Deemed Safe In ...
Bidness ETC - May 14, 2015
AstraZeneca plc (ADR) (NYSE:AZN) and Novartis AG (ADR) (NYSE:NVS) have partnered up to develop a three-drug combination treatment for a life-threatening form of skin cancer, melanoma.
Technical Insights on Novartis AG (ADR) (NYSE:NVS)
Markets Wired - Apr 23, 2015
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) the world's biggest drugmaker by sales, reported first-quarter profit that beat analysts' estimates as the company begins to benefit from a set of transactions that make it smaller and more ...
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets - Bidness ETC
Novartis AG's (ADR) (NYSE:NVS) (ADR) Looking For Buyout in the Range of $2 ... - WallStreetPR (blog)
Novartis AG (ADR) Biosimilar Blocked By US Appeals Court
Bidness ETC - May 8, 2015
The US Appeals court has blocked Novartis AG (ADR) (NYSE:NVS) from selling a copy of Amgen, Inc.'s (NASDAQ:AMGN) cancer supportive-care drug in the US for an indefinite period of time - or at least until June 3, when verbal arguments are scheduled, ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
Bidness ETC - Mar 2, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ... - Stocks.org
GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge - FiercePharma
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
Bidness ETC - Feb 26, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (NYSE:NVS) & GlaxoSmithKline PLC (NYSE:GSK) Receive a Green ... - WallStreet.org
Sanofi SA (ADR) (SNY) And Novartis AG Lead In US New Drug Approvals Since ...
Bidness ETC - May 8, 2015
According to a recent Bloomberg report, Sanofi SA (ADR) (NYSE:SNY) and Novartis AG (ADR) (NYSE:NVS) have launched the highest number of drugs in the US since 2009.